Cancer Family
Myeloid Neoplasm
CI-CAN-00000279Explore in graph →
HematologicNon-malignant1,102 active trials29 approved drugs653 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000279Explore in graph →
Clinical trials
4,789 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00037583 | Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia | completed | Phase 2 | 69 | Wyeth is now a wholly owned subsidiary of PfizerINDUSTRY | 0 | Aug 21, 2009 | clinicaltrials |
| NCT00373373 | Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML | completed | Phase 2 | 200 | University Hospital MuensterOTHER | 1 | Aug 19, 2009 | clinicaltrials |
| NCT00306332 | T-cell and B-cell Depletion in Allogeneic Peripheral Blood Stem Cell Transplantation | terminated | Phase 3 | 250 | Radboud University Medical CenterOTHER | 1 | Aug 18, 2009 | clinicaltrials |
| NCT00510939 | Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia(HEMOS AML 0106) | unknown | Phase 2 | 72 | University of BolognaOTHER | 1 | Aug 14, 2009 | clinicaltrials |
| NCT00598624 | Clinical Trial to Evaluate the Safety and Efficacy of Treosulfan Based Conditioning Prior to Allogeneic Haematopoietic Stem Cell Transplantation (HSCT)(AlloTreo) | unknown | Phase 2 | 175 | IRCCS San RaffaeleOTHER | 1 | Aug 11, 2009 | clinicaltrials |
| NCT00899327 | Biomarkers in Patients at Risk of Developing Myelodysplastic Syndrome or Other Disorders and in Healthy Participants | unknown | — | 200 | Oxford University Hospitals NHS TrustOTHER | 1 | Jul 8, 2009 | clinicaltrials |
| NCT00931138 | Treatment of Acute Myeloid Leukemia (AML) in Adults 50 to 70 Years, Study of Two Anthracyclines and the Interest of Maintenance Treatment With Interleukin 2(ALFA 9801) | completed | Phase 3 | 420 | Acute Leukemia French AssociationOTHER | 1 | Jul 2, 2009 | clinicaltrials |
| NCT00925873 | GOELAMS SA4 Study: the Role of Fludarabine in the Treatment of Acute Myeloid Leukemia in the Elderly | completed | Phase 3 | 303 | French Innovative Leukemia OrganisationOTHER | 1 | Jun 22, 2009 | clinicaltrials |
| NCT00466843 | Effects of Antithymocyte Globulin in Adults With Myelodysplastic Syndrome | unknown | Phase 2 | 54 | Office of Rare Diseases (ORD)NIH | 1 | Jun 2, 2009 | clinicaltrials |
| NCT00352677 | Safety and Tolerability Study of INNO-406 to Treat Chronic Myeloid Leukemia or Acute Lymphocytic Leukemia | completed | Phase 1 | 100 | CytRxINDUSTRY | 3 | Jun 1, 2009 | clinicaltrials |
| NCT00543972 | Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia | terminated | Phase 1 | 12 | SanofiINDUSTRY | 3 | May 14, 2009 | clinicaltrials |
| NCT00003681 | Amifostine With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome | unknown | Phase 2 | 50 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 7 | May 12, 2009 | clinicaltrials |
| NCT00391014 | Nebulized Liposomal Amphotericin B Ambisome for Prophylaxis of Invasive Pulmonary Aspergillosis(AMBINEB) | completed | Phase 2 | 150 | PETHEMA FoundationOTHER | 1 | May 12, 2009 | clinicaltrials |
| NCT00506402 | A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies | completed | Phase 1 | 30 | CASI pharmaceuticals, Inc.INDUSTRY | 1 | May 5, 2009 | clinicaltrials |
| NCT00880243 | Effect of Priming During Induction and Consolidations in Younger Acute Myeloid Leukemia (AML) | completed | Phase 3 | 473 | Acute Leukemia French AssociationOTHER | 0 | Apr 13, 2009 | clinicaltrials |
| NCT00064584 | Safety and Tolerance Study of Oral Doses of CT53518 to Treat Patients With Acute Myelogenous Leukemia (AML) | completed | Phase 1 | 60 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 24, 2009 | clinicaltrials |
| NCT00866073 | Study of Low-Dose Intravenous Decitabine in Patients Aged > 60 Years With Acute Myeloid Leukemia | completed | Phase 2 | 238 | University Hospital FreiburgOTHER | 2 | Mar 20, 2009 | clinicaltrials |
| NCT00854841 | The Randomized Study of Dasatinib and High-Dose Imatinib (600mg) in Suboptimal Responder | available | — | — | Pusan National University HospitalOTHER | 0 | Mar 3, 2009 | clinicaltrials |
| NCT00257647 | Use of SV40 Vectors to Treat Chronic Myeloid Leukemia (CML) | completed | — | 25 | Hadassah Medical OrganizationOTHER | 1 | Feb 18, 2009 | clinicaltrials |
| NCT00145613 | Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies | completed | Phase 2 | 25 | St. Jude Children's Research HospitalOTHER | 1 | Feb 13, 2009 | clinicaltrials |
| NCT00461929 | Chromosome Abnormalities in Chronic Myeloid Leukemia (CML) on Imatinib. GIST Patients on Imatinib(GIST) | terminated | Phase 4 | 68 | University Health Network, TorontoOTHER | 1 | Feb 13, 2009 | clinicaltrials |
| NCT00002989 | Combination Chemotherapy With or Without Idarubicin and Peripheral Stem Cell Transplantation in Treating Patients With Leukemia or Myelodysplastic Syndrome | unknown | Phase 3 | 207 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 5 | Feb 9, 2009 | clinicaltrials |
| NCT00146120 | Risk-Adapted Therapy of Acute Myeloid Leukemia of Adults (18-60 Years) According to the Cytogenetic Result | completed | Phase 3 | 400 | University of UlmOTHER | 2 | Feb 9, 2009 | clinicaltrials |
| NCT00707408 | High-Dose Imatinib for Relapsed/Refractory c-Kit Positive Acute Myelogenous Leukemia (AML) | completed | Phase 2 | 15 | Nantes University HospitalOTHER | 1 | Feb 2, 2009 | clinicaltrials |
| NCT00086099 | Study Evaluating the Addition of Amifostine (Ethyol®) to Idarubicin and Cytosine Arabinoside in Older Patients With Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 54 | MedImmune LLCINDUSTRY | 2 | Jan 29, 2009 | clinicaltrials |
| NCT00143559 | Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies | completed | Phase 2 | 17 | St. Jude Children's Research HospitalOTHER | 1 | Jan 29, 2009 | clinicaltrials |
| NCT00152139 | Stem Cell Transplantation for Patients With Hematologic Malignancies | completed | Phase 3 | 33 | St. Jude Children's Research HospitalOTHER | 1 | Jan 29, 2009 | clinicaltrials |
| NCT00186823 | Haploidentical Stem Cell Transplantation for Patients With Hematologic Malignancies | completed | Phase 3 | 57 | St. Jude Children's Research HospitalOTHER | 1 | Jan 29, 2009 | clinicaltrials |
| NCT00516152 | Phase II Study Evaluating Busulfan and Fludarabine as Preparative Therapy in Adults With Hematopoietic Disorders Undergoing MUD SCT | completed | Phase 2 | 36 | University of California, San FranciscoOTHER | 1 | Jan 26, 2009 | clinicaltrials |
| NCT00815568 | Feasibility and Efficacy Study of Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) With Fludarabine, Busulfan, and Total Body Irradiation (TBI) | unknown | Phase 2 | 114 | Samsung Medical CenterOTHER | 1 | Dec 30, 2008 | clinicaltrials |
| NCT00467792 | Natural History of Urticaria Pigmentosa in Children(UP) | completed | — | 47 | Medical College of WisconsinOTHER | 1 | Dec 8, 2008 | clinicaltrials |
| NCT00390897 | Glivec® (Imatinib Mesylate, STI571) in Monotherapy Versus Glivec®-Interferon Alpha in the Treatment of Chronic-Phase Chronic Myeloid Leukaemia | completed | Phase 4 | 360 | PETHEMA FoundationOTHER | 1 | Nov 27, 2008 | clinicaltrials |
| NCT00487448 | SMD_FLAG-IDA_98: FLAG-IDA in Induction Treatment of High Risk Myelodysplastic Syndromes or Secondary Acute Myeloblastic Leukemia(FLAG-IDA) | completed | Phase 4 | 200 | PETHEMA FoundationOTHER | 1 | Nov 19, 2008 | clinicaltrials |
| NCT00488709 | Fludarabine, Cytarabine, Topotecan in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia(FLAT) | completed | Phase 4 | 47 | PETHEMA FoundationOTHER | 1 | Nov 18, 2008 | clinicaltrials |
| NCT00114764 | Trial Comparing Pegfilgrastim With Filgrastim as an Adjunct to Chemotherapy for Acute Myeloid Leukaemia (AML) | completed | Phase 2 | 84 | AmgenINDUSTRY | 0 | Oct 31, 2008 | clinicaltrials |
| NCT00594555 | A Study Evaluating the Effects of CLAG With Gleevec in Refractory or Relapsed Acute Myeloid Leukemia | withdrawn | Phase 2 | 20 | University of CincinnatiOTHER | 1 | Oct 31, 2008 | clinicaltrials |
| NCT00559221 | FLAG+Ida With G-CSF Priming for Patients Younger Than 60 Years With Resistant AML | unknown | Phase 2 | 37 | Cooperative Study Group A for HematologyNETWORK | 1 | Oct 15, 2008 | clinicaltrials |
| NCT00001144 | Modified Bone Marrow Stem Cell Transplantation for Chronic Myelogenous Leukemia | completed | Phase 2 | 50 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Oct 7, 2008 | clinicaltrials |
| NCT00728520 | Trial With Azacitidine in Newly Diagnosed Acute Myelogenous Leukemia (AML) Veterans Administration (VA) Elderly Patients Not Eligible for Standard Induction Therapy | unknown | Phase 2 | 40 | Kansas City Veteran Affairs Medical CenterFED | 1 | Aug 6, 2008 | clinicaltrials |
| NCT00700544 | Treatment Outcome in Elderly Patients | completed | Phase 3 | 330 | University Hospital, GrenobleOTHER | 1 | Jun 18, 2008 | clinicaltrials |
| NCT00675870 | Study of NRX 195183 Therapy for Patients With Relapsed or Refractory Acute Promyelocytic Leukemia | unknown | Phase 2 | 65 | NuRx Pharmaceuticals, Inc.INDUSTRY | 1 | May 12, 2008 | clinicaltrials |
| NCT00667927 | Autologous Bone Marrow Transplant for Children With Acute Myelogenous Leukemia (AML) in First Complete Remission | completed | Phase 1 | 17 | St. Jude Children's Research HospitalOTHER | 1 | Apr 28, 2008 | clinicaltrials |
| NCT00129168 | Zosuquidar in Combination With Daunorubicin and Cytarabine in Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia (AML) | completed | Phase 1 / Phase 2 | 100 | Kanisa PharmaceuticalsINDUSTRY | 0 | Apr 1, 2008 | clinicaltrials |
| NCT00233909 | A Trial of Gemtuzumab Ozogamicin (GO) in Combination With Zosuquidar in Patients With CD33 Positive Acute Myeloid Leukemia | completed | Phase 1 / Phase 2 | 55 | Kanisa PharmaceuticalsINDUSTRY | 0 | Apr 1, 2008 | clinicaltrials |
| NCT00465933 | Treatment of Acute Promyelocytic Leukemia With All-Trans Retinoic Acid (ATRA) and Idarubicin (AIDA) | completed | Phase 4 | — | PETHEMA FoundationOTHER | 1 | Mar 31, 2008 | clinicaltrials |
| NCT00001356 | Characteristics of Mast Cells in Mastocytosis | completed | — | 300 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001432 | The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic Malignancies | completed | — | 75 | National Cancer Institute (NCI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001748 | HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies | completed | Phase 1 | 35 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00001839 | A Randomized Trial of Antithymocyte Globulin Versus Cyclosporine to Treat the Cytopenia of Myelodysplastic Syndrome | completed | Phase 2 | 182 | National Institutes of Health Clinical Center (CC)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00047918 | Blood Factors in Mastocytosis and Unexplained Anaphylaxis and Flushing | completed | — | 100 | National Institute of Allergy and Infectious Diseases (NIAID)NIH | 1 | Mar 4, 2008 | clinicaltrials |
Data updated 22 days agoSource updated Aug 21, 2009source: clinicaltrials